A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival

Restricted access

Object. The extent of tumor resection that should be undertaken in patients with glioblastoma multiforme (GBM) remains controversial. The purpose of this study was to identify significant independent predictors of survival in these patients and to determine whether the extent of resection was associated with increased survival time.

Methods. The authors retrospectively analyzed 416 consecutive patients with histologically proven GBM who underwent tumor resection at the authors' institution between June 1993 and June 1999. Volumetric data and other tumor characteristics identified on magnetic resonance (MR) imaging were collected prospectively.

Conclusions. Five independent predictors of survival were identified: age, Karnofsky Performance Scale (KPS) score, extent of resection, and the degree of necrosis and enhancement on preoperative MR imaging studies. A significant survival advantage was associated with resection of 98% or more of the tumor volume (median survival 13 months, 95% confidence interval [CI] 11.4–14.6 months), compared with 8.8 months (95% CI 7.4–10.2 months; p < 0.0001) for resections of less than 98%. Using an outcome scale ranging from 0 to 5 based on age, KPS score, and tumor necrosis on MR imaging, we observed significantly longer survival in patients with lower scores (1–3) who underwent aggressive resections, and a trend toward slightly longer survival was found in patients with higher scores (4–5). Gross-total tumor resection is associated with longer survival in patients with GBM, especially when other predictive variables are favorable.

Article Information

Address reprint requests to: Raymond Sawaya, M.D., Department of Neurosurgery, Box 442, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030.

© AANS, except where prohibited by US copyright law."

Headings

Figures

  • View in gallery

    Grades of tumor necrosis adapted from Hammoud, et al. are demonstrated on MR images. The amount of tumor necrosis, which appears as an area of decreased signal intensity on T1-weighted images, was divided into four grades as follows: Grade 0, no necrosis apparent on the MR image; Grade I, amount of necrosis less than 25% of the tumor volume; Grade II, amount of necrosis 25 to 50% of the tumor volume; and Grade III, amount of necrosis greater than 50% of the tumor volume.

  • View in gallery

    Axial T1- (left) and T2-weighted MR images (right) obtained in a patient with GBM. There was no enhancement of the tumor on the gadolinium-enhanced T1-weighted images. In such cases, tumor volume was defined as the region of T2 signal abnormality corresponding to the mass seen on both T1- and T2-weighted images (excluding the ill-defined hyperintense signal abnormality surrounding the mass on T2-weighted images).

  • View in gallery

    Contrast-enhanced axial T1-weighted MR images obtained in a patient with GBM. Preoperative (left) and postoperative images (right) demonstrate a gross-total tumor resection.

  • View in gallery

    Graph showing Kaplan—Meier estimates of overall survival after index surgery in all patients. Overall survival time was significantly longer among patients who underwent resection of 98% or more of the tumor volume (197 of 416, p < 0.0001) than among patients with a less than 98% tumor resection (219 of 416).

  • View in gallery

    Graph showing Kaplan—Meier estimates of survival after index surgery for the entire patient population with respect to the different outcome groups. Log-rank test probability value is less than 0.0001.

  • View in gallery

    Graphs showing Kaplan—Meier estimates of survival after index surgery for the entire patient population with respect to different outcome groups and by extent of tumor resection. A trend toward longer survival was found in Group A patients (A) who underwent resection of 98% or more of the tumor volume; however, the number of patients was too small to reveal significance. The median survival time was longer in Group B patients (B) who underwent resection of 98% or more of the tumor volume (p = 0.001) than in those whose resections were below that level; the same was found in Group C patients (C) (p = 0.005). There was a trend toward slightly longer survival times after more aggressive resections in Group D patients (D) (p = 0.13).

References

1.

Albert FKForsting MSartor Ket al: Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 34:45611994Neurosurgery 34:

2.

Ammirati MGalicich JHArbit Eet al: Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 21:6076141987Neurosurgery 21:

3.

Ammirati MVick NLiao Yet al: Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. Neurosurgery 21:2012061987Neurosurgery 21:

4.

Andreou JGeorge AEWise Aet al: CT prognostic criteria of survival after malignant glioma surgery. AJNR 4:4884901983AJNR 4:

5.

Avellanosa AMWest CRTsukada Yet al: Chemotherapy of nonirradiated malignant gliomas. Phase II: study of the combination of methyl-CCNU, vincristine, and procarbazine. Cancer 44:8398461979Cancer 44:

6.

Burger PCGreen SB: Patient age, histological features, and length of survival in patients with glioblastoma multiforme. Cancer 59:161716251987Cancer 59:

7.

Cox DR: Regression models and life tables. J R Stat Soc B 34:1872201972Cox DR: Regression models and life tables. J R Stat Soc B 34:

8.

Curran WJ JrScott CBHorton Jet al:Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials. J Neurooncol 12:2192271992J Neurooncol 12:

9.

Daumas-Duport CScheithauer BO'Fallon Jet al: Grading of astrocytomas. A simple and reproducible method. Cancer 62:215221651988Cancer 62:

10.

Earnest F IVKelly PJScheithauer BWet al: Cerebral astrocytomas: histopathological correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology 166:8238271988Radiology 166:

11.

Fadul CWood JThaler Het al: Morbidity and mortality of craniotomy for excision of supratentorial gliomas. Neurology 38:137413791988Neurology 38:

12.

Gehan EAWalker MD: Prognostic factors for patients with brain tumors. Natl Cancer Inst Monogr 46:1891951977Natl Cancer Inst Monogr 46:

13.

Gilbert HKagan ARCassidy Fet al: Glioblastoma multiforme is not a uniform disease. Cancer Clin Trials 4:87891981Cancer Clin Trials 4:

14.

Hammoud MASawaya RShi Wet al: Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol 27:65731996J Neurooncol 27:

15.

Harsh GR IVLevin VAGutin PHet al: Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery 21:6156211987Neurosurgery 21:

16.

Hess KR: Extent of resection as a prognostic variable in the treatment of gliomas. J Neurooncol 42:2272311999Hess KR: Extent of resection as a prognostic variable in the treatment of gliomas. J Neurooncol 42:

17.

Kaplan ELMeier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:4574811958J Am Stat Assoc 53:

18.

Kelly PJ: Stereotactic biopsy and resection of thalamic astrocytomas. Neurosurgery 25:1851951989Kelly PJ: Stereotactic biopsy and resection of thalamic astrocytomas. Neurosurgery 25:

19.

Kelly PJDaumas-Duport CKispert DBet al: Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg 66:8658741987J Neurosurg 66:

20.

Kiwit JCFloeth FWBock WJ: Survival in malignant glioma: analysis of prognostic factors with special regard to cytoreductive surgery. Zentralbl Neurochir 57:76881996Zentralbl Neurochir 57:

21.

Kleihues PBurger PCScheithauer BWet al: Histological Typing of Tumours of the Central Nervous Systemed 2. New York: Springer-Verlag1993

22.

Kreth FWWarnke PCScheremet Ret al: Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme. J Neurosurg 78:7627661993J Neurosurg 78:

23.

Lai DMLin SMTu YKet al: Therapy for supratentorial malignant astrocytomas: survival and possible prognostic factors. J Formos Med Assoc 92:2202261993J Formos Med Assoc 92:

24.

Nazzaro JMNeuwelt EA: The role of surgery in the management of supratentorial intermediate and high-grade astrocytoma in adults. J Neurosurg 73:3313441990J Neurosurg 73:

25.

Newell JRansohoff JKaplan B: Glioblastoma in the older patient: how long a course of radiotherapy is necessary? J Neurooncol 6:3253271988J Neurooncol 6:

26.

Nitta TSato K: Prognostic implications of the extent of surgical resection in patients with intracranial malignant gliomas. Cancer 75:272727311995Cancer 75:

27.

Prados MDGutin PHPhillips TLet al: Highly anaplastic astrocytoma: a review of 357 patients treated between 1977 and 1989. Int J Radiat Oncol Biol Phys 23:381992Int J Radiat Oncol Biol Phys 23:

28.

Quigley MRMaroon JC: The relationship between survival and the extent of resection in patients with supratentorial malignant gliomas. Neurosurgery 29:3853891991Neurosurgery 29:

29.

Ringertz N: “Grading” of gliomas. Acta Pathol Microbiol Scand 27:51641950Ringertz N: “Grading” of gliomas. Acta Pathol Microbiol Scand 27:

30.

Salcman M: Resection and reoperation in neuro-oncology. Rationale and approach. Neurol Clin 3:8318421985Salcman M: Resection and reoperation in neuro-oncology. Rationale and approach. Neurol Clin 3:

31.

Salcman M: Surgical decision-making for malignant brain tumors. Clin Neurosurg 35:2853131989Salcman M: Surgical decision-making for malignant brain tumors. Clin Neurosurg 35:

32.

Sawaya R: Extent of resection in malignant gliomas: a critical summary. J Neurooncol 42:3033051999Sawaya R: Extent of resection in malignant gliomas: a critical summary. J Neurooncol 42:

33.

Sawaya RHammoud MSchoppa Det al: Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery 42:104410561998Neurosurgery 42:

34.

Scott GMGibberd FB: Epilepsy and other factors in the prognosis of gliomas. Acta Neurol Scand 61:2272391980Acta Neurol Scand 61:

35.

Segall HDDestian SNelson MD Jret al: CT and MR imaging in malignant gliomasApuzzo MLJ (ed): Malignant Cerebral Glioma. Park Ridge, IL: American Association of Neurological Surgeons19906377Malignant Cerebral Glioma.

36.

Shapiro WRGreen SBBurger PCet al: Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant gliomas. Brain Tumor Cooperative Group Trial 8001. J Neurosurg 71:191989J Neurosurg 71:

37.

Shi WMWildrick DMSawaya R: Volumetric measurement of brain tumors from MR imaging. J Neurooncol 37:87931998J Neurooncol 37:

38.

Walker MDGreen SBByar DPet al: Randomized comparisons of radiotherapy and nitrosoureas for treatment of malignant glioma after surgery. N Engl J Med 303:132313291980N Engl J Med 303:

39.

Wood JRGreen SBShapiro WR: The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol 6:3383431988J Clin Oncol 6:

TrendMD

Cited By

Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 18 18 18
Full Text Views 416 416 256
PDF Downloads 184 184 142
EPUB Downloads 0 0 0

PubMed

Google Scholar